A ruling by the US Patent and Trademark Office has reignited the krill wars, with Norwegian company Rimfrost AS claiming the ruling could invalidate all of the claims relating to two patents held by rival Aker BioMarine AS.
In what one side is billing as the final act in the krill wars in North America, the US Patent and Trademark Office has ruled to uphold certain claims of a longstanding patent held by Neptune Technologies and Bioressources. But the handle of the buried...
Some things have seemed immutable: Death. Taxes. The Krill Wars. But the latter has (mostly) fallen off that list with the announcement this morning that fierce competitors Neptune Technologies & Bioressources and Aker BioMarine have reached an 11th-hour...
In another busy day in the ongoing struggle among krill oil suppliers over IP protection, a trade complaint was filed, this time with the International Trade Commission, and the re-examination of a patent passed a procedural benchmark that one company...
Suggestions by Aker Biomarine that Neptune Technologies and Bioressources misrepresented the novelty of the inventions claimed in its newly-granted krill oil patent are “baseless”, Neptune bosses have insisted.
Neptune Technologies & Bioressources has bolstered its intellectual property portfolio further after securing a new US patent (No. 8,057,825) awarding it the exclusive use of krill extracts in the US as a method for reducing cholesterol, platelet...
Canadian R&D company Burcon has been granted a new US patent on
its process for producing flax protein isolates - an innovation
said to result in a higher protein yield and improved product.
Sabinsa Corporation announced it has secured a patent in Canada for
its standardized black pepper extract Bioperine, thereby giving the
company proprietary rights to the ingredient throughout North
America.
The US Patent and Trademark Office has completed a formal review of
Sabinsa Corporation'spatent for black pepper extract, BioPerine,
and has found the intellectual property to be valid.
Clearing the final hurdle for a new patent, nutraceutical company
NutraCea could soon be marketing its stabilised rice bran
derivatives on the back of claims to beat cardiovascular disease.
